Explore our Resources
Access a curated collection of materials designed to provide insights into our capabilities and expertise across the drug development and manufacturing lifecycle.
Resources
Industry Perspective
OneSource goes for multi-modality to build a global pharma platform
Neeraj Sharma, CEO & Managing Director, OneSource Specialty Pharma Published on Business India Source: OneSource goes for multi-modality to build a global pharma platform OneSource Specialty Pharma Ltd is a new name…
Industry Perspective
AI Reality Check: CFOs Highlight the Biggest Challenges for Mid-Sized Organizations
Anurag Bhagania, CFO, OneSource Specialty Pharma Published on Financial Express CFO Source: AI Reality Check: CFOs Highlight the Biggest Challenges for Mid-Sized Organizations The finance leaders suggest that while AI promises significant…
Whitepaper
Beyond the Molecule: Human Factors Engineering as the Competitive Edge in Drug-Device Combination Products
The molecule isn’t the differentiator anymore. The device is. What this whitepaper covers: How an integrated CDMO turns device usability into commercial advantage for self-administered drug-device combination products. Whitepaper Abstract: For a…
Industry Perspective
Cyber Risk is now a financial risk: Why pharma boards can’t look away
Anurag Bhagania, CFO, OneSource Specialty Pharma Published on ET Edge Insights Source: Cyber Risk is now a financial risk: Why pharma boards can’t look away – ET Edge Insights Cyber risk is…
Whitepaper
Lyophilization by Design: Engineering Stability, Speed, and Scale into the Next Generation of Parenteral Products
What this whitepaper covers: Why lyophilization has become a defining constraint in modern biologics development — and how a QbD-led, integrated approach transforms cycle design into a scalable, regulatory-ready system. Whitepaper Abstract:…
Industry Perspective
The quiet revolution in how we take our medicine
The quiet revolution in how we take our medicine Ravi Kumar, Global Head of Injectables & Corporate Strategy, Portfolio and SPO Published on Money Control, 05 Jun 2026 Three out of four…
Whitepaper
Bioavailability by Design: Lipid Softgel Technology as a Commercial Rescue Path for Poorly Soluble, Low-Bioavailability Molecules
Solubility is broken. The pipeline proves it. What this whitepaper covers: Why solubility failure is the defining challenge of modern oral drug development — and how self-emulsifying softgel technology (SEDDS/SMEDDS/SNEDDS) unlocks bioavailability…
Whitepaper
Driving the Shift to Subcutaneous Biologics
The subcutaneous shift has already happened. Is your pipeline ready? In 2000–2004, 25% of FDA biologic approvals were device-based. By 2023-2025, 74% were. OneSource delivers the complete subcutaneous (SC) development stack –…
On-Demand Webinar
Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical Development
GLP-1 peptide therapeutics are rapidly reshaping the treatment landscape for diabetes and obesity, increasing the need for robust formulation development and comprehensive analytical characterization strategies that enable safe, scalable, and market-ready drug…